Axonics Modulation Technologies Inc (AXNX) COO Rinda Sama Sells 13,345 Shares

Axonics Modulation Technologies Inc (NASDAQ:AXNX) COO Rinda Sama sold 13,345 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $28.03, for a total value of $374,060.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AXNX opened at $31.44 on Wednesday. Axonics Modulation Technologies Inc has a 12-month low of $11.95 and a 12-month high of $32.90. The company has a debt-to-equity ratio of 0.16, a quick ratio of 27.46 and a current ratio of 22.83. The firm has a market cap of $817.67 million and a PE ratio of -6.78.

Axonics Modulation Technologies (NASDAQ:AXNX) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.18). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.24 million. On average, equities analysts expect that Axonics Modulation Technologies Inc will post -1.66 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of AXNX. Citigroup Inc. bought a new position in shares of Axonics Modulation Technologies during the 4th quarter worth $28,000. Barclays PLC bought a new position in shares of Axonics Modulation Technologies during the 4th quarter worth $31,000. New York State Common Retirement Fund bought a new position in shares of Axonics Modulation Technologies during the 1st quarter worth $60,000. American International Group Inc. bought a new position in shares of Axonics Modulation Technologies during the 4th quarter worth $69,000. Finally, Deutsche Bank AG bought a new position in shares of Axonics Modulation Technologies during the 4th quarter worth $137,000. 31.93% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on AXNX shares. SunTrust Banks upped their price objective on Axonics Modulation Technologies to $26.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Zacks Investment Research raised Axonics Modulation Technologies from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research report on Thursday, February 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.38.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.wkrb13.com/2019/05/15/axonics-modulation-technologies-inc-axnx-coo-rinda-sama-sells-13345-shares.html.

Axonics Modulation Technologies Company Profile

Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.

Further Reading: Technical Analysis

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.